Home » Germany Boosts CureVac, BioNTech COVID-19 Vaccine Programs With New Grants
Germany Boosts CureVac, BioNTech COVID-19 Vaccine Programs With New Grants
Germany’s government has granted $445 million to BioNTech and $297 million to CureVac to help the two German companies accelerate their COVID-19 vaccine development efforts.
The funding will go toward clinical development and the scaling up of manufacturing capacity for the companies’ messenger RNA (mRNA)-based vaccines.
The synthetic vaccines are designed to generate antibodies to the SARS-CoV-2 virus that causes COVID-19. They offer some advantages over existing vaccine technology because they are easier to scale up. But the technology is new, and no mRNA vaccines are currently approved for human use.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May